Alterations of the cell-cycle inhibitors p27 KIP1 and p16 INK4a are frequent in blastic plasmacytoid dendritic cell neoplasms

Thomas Wiesner, Anna C. Obenauf, Carlo Cota, Isabella Fried, Michael R. Speicher, Lorenzo Cerroni

Research output: Contribution to journalArticlepeer-review

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive malignancy with a median survival of 12-14 months. To identify pathogenetic relevant genomic aberrations and molecular targets for therapy, we analyzed skin biopsy samples obtained from 14 patients using high-resolution array-based comparative genomic hybridization and immunostaining. Losses of chromosomes 9, 12, 13, and 15 were detected most frequently. Loss of the CDKN1B locus was the most common finding and was detected in 64% of tumors. In all but one case, the dose-dependent haploinsufficient cell-cycle inhibitor p27 KIP1, encoded by CDKN1B, was weakly expressed in the nuclei of tumor cells. Losses of the CDKN2A-ARF-CDKN2B locus occurred in 50% of patients, and in one case a distinct biallelic loss was identified. The cell-cycle inhibitor p16 INK4a, which is encoded by CDKN2A, was not expressed in tumor cells, suggesting a complete loss of function. Loss of chromosome 13, including the RB1 gene, was observed in 43% of tumors. These results imply that alterations of the cell-cycle checkpoint controlling proteins p27 KIP1, p16 INK4a, and RB1 may exert a profound effect in malignant transformation in BPDCN. The elucidation of the affected pathways may guide the development of new treatments specifically designed for this aggressive disease entity.

Original languageEnglish
Pages (from-to)1152-1157
Number of pages6
JournalJournal of Investigative Dermatology
Volume130
Issue number4
DOIs
Publication statusPublished - Apr 2010

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Alterations of the cell-cycle inhibitors p27 KIP1 and p16 INK4a are frequent in blastic plasmacytoid dendritic cell neoplasms'. Together they form a unique fingerprint.

Cite this